Overview

Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759

Status:
Active, not recruiting
Trial end date:
2020-11-30
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, dose escalation and phase I/II study, consisting of dose escalation in Part A and phase II study in Part B.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
LYZZ Alpha Holding Ltd
Collaborator:
Tigermed Consulting Co., Ltd